Company intelligence / Profile preview

Shaphar

Ownership: Private
Development stage: Other

Overview

Shaphar is an early-stage biotechnology company focused on the discovery and development of novel molecular glue degraders. The company leverages a proprietary platform to identify small molecules that induce the degradation of disease-causing proteins by facilitating their interaction with E3 ubiquitin ligases. Shaphar's primary therapeutic focus is in oncology, where it aims to target previously undruggable proteins involved in cancer progression. By expanding the scope of targeted protein degradation, the company seeks to develop highly specific and potent therapies for patients with limited treatment options.

Therapeutic areas: Oncology
Modalities: Small moleculeMolecular glue therapy
Industry: Biotech

Beyond the preview

Go deeper on Shaphar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shaphar.

Explore the full profile